Compare MasTec Inc (MTZ) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Smith & Nephew plc — how do they compare? MasTec Inc trades at $214.28 (market cap $17.40B), while Smith & Nephew plc trades at $27.31 (market cap $11.10B). The key difference: MasTec Inc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while MasTec Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MasTec Inc for 23 Days and Smith & Nephew plc for 120 Days on average.
| MTZ | SNN | |
|---|---|---|
Market Cap | $17.40B | $11.10B |
Volume | 1,415,821 | 1,051,703 |
Sector | Industrials | Health |
52-Week High | $437.51 | $37.17 |
52-Week Low | $190.08 | $26.42 |
Typical Hold Time | 23 Days | 120 Days |
Enterprise Value | $20.32B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $223.37, down 2.16% on the day, with technical indicators showing a neutral to bearish short-term bias. The company demonstrates strong fundamentals with Q1 2026 earnings beating expectations and a robust 88.9% analyst buy rating. Recent news highlights MTZ's positioning to benefit from infrastructure investment cycles, particularly in power delivery and data center markets, supported by a record $21.4 billion backlog.
The outlook remains positive given strong institutional support and infrastructure tailwinds, though premium valuation and communications segment softness pose risks. With a consensus price target of $408.58 representing 83% upside potential, the stock offers significant growth opportunity for investors comfortable with execution risks in the competitive infrastructure sector.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
